Traditionally, therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) consists of BCR-ABL tyrosine kinase inhibitor (TKI) plus intensive multi-agent chemotherapy, which is associated with prolonged myelosuppression and life-threatening cytopenias. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.